Scholars@Duke

In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4+ T-Cells.

Publication ,  Journal Article
Bissa, M; Galli, V; Schifanella, L; Vaccari, M; Rahman, MA; Gorini, G; Binello, N; Sarkis, S; Gutowska, A; Silva de Castro, I; Doster, MN ...
Published in: Vaccines (Basel)
October 30, 2023
Published version (DOI) Link to item

At the heart of the DNA/ALVAC/gp120/alum vaccine's efficacy in the absence of neutralizing antibodies is a delicate balance of pro- and anti-inflammatory immune responses that effectively decreases the risk of SIVmac251 acquisition in macaques. Vaccine efficacy is linked to antibodies recognizing the V2 helical conformation, DC-10 tolerogenic dendritic cells eliciting the clearance of apoptotic cells via efferocytosis, and CCR5 downregulation on vaccine-induced gut homing CD4+ cells. RAS activation is also linked to vaccine efficacy, which prompted the testing of IGF-1, a potent inducer of RAS activation with vaccination. We found that IGF-1 changed the hierarchy of V1/V2 epitope recognition and decreased both ADCC specific for helical V2 and efferocytosis. Remarkably, IGF-1 also reduced the expression of CCR5 on vaccine-induced CD4+ gut-homing T-cells, compensating for its negative effect on ADCC and efferocytosis and resulting in equivalent vaccine efficacy (71% with IGF-1 and 69% without).

Duke Scholars

Xiaoying Shen
Author Xiaoying Shen Surgery, Surgical Sciences
Guido Ferrari
Author Guido Ferrari Surgery, Surgical Sciences
David Charles Montefiori
Author David Charles Montefiori Surgery, Surgical Sciences
Georgia Doris Tomaras
Author Georgia Doris Tomaras Surgery, Surgical Sciences

Published In

Vaccines (Basel)

DOI

10.3390/vaccines11111662

ISSN

2076-393X

Publication Date

October 30, 2023

Volume

11

Issue

11

Location

Switzerland

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bissa, M., Galli, V., Schifanella, L., Vaccari, M., Rahman, M. A., Gorini, G., … Franchini, G. (2023). In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4+ T-Cells. Vaccines (Basel), 11(11). https://doi.org/10.3390/vaccines11111662
Bissa, Massimiliano, Veronica Galli, Luca Schifanella, Monica Vaccari, Mohammad Arif Rahman, Giacomo Gorini, Nicolò Binello, et al. “In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4+ T-Cells.” Vaccines (Basel) 11, no. 11 (October 30, 2023). https://doi.org/10.3390/vaccines11111662.
Bissa M, Galli V, Schifanella L, Vaccari M, Rahman MA, Gorini G, et al. In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4+ T-Cells. Vaccines (Basel). 2023 Oct 30;11(11).
Bissa, Massimiliano, et al. “In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4+ T-Cells.” Vaccines (Basel), vol. 11, no. 11, Oct. 2023. Pubmed, doi:10.3390/vaccines11111662.
Bissa M, Galli V, Schifanella L, Vaccari M, Rahman MA, Gorini G, Binello N, Sarkis S, Gutowska A, Silva de Castro I, Doster MN, Moles R, Ferrari G, Shen X, Tomaras GD, Montefiori DC, N’guessan KF, Paquin-Proulx D, Kozlowski PA, Venzon DJ, Choo-Wosoba H, Breed MW, Kramer J, Franchini G. In Vivo Treatment with Insulin-like Growth Factor 1 Reduces CCR5 Expression on Vaccine-Induced Activated CD4+ T-Cells. Vaccines (Basel). 2023 Oct 30;11(11).

Published In

Vaccines (Basel)

DOI

10.3390/vaccines11111662

ISSN

2076-393X

Publication Date

October 30, 2023

Volume

11

Issue

11

Location

Switzerland

Related Subject Headings

  • 3207 Medical microbiology
  • 3204 Immunology
  • 3202 Clinical sciences